Annual Report 2011

Stockholm, May 22, 2012 – Karo Bio AB’s annual report for 2011 is as of today available on the company’s website www.karobio.com.

The printed version of the annual report will be distributed to shareholders and others specifically subscribing to the printed version. It can also be ordered from Karo Bio by mail to Karo Bio AB, attn: Eva Kruse, Novum, 141 57 Huddinge, Sweden, by fax to +46 8 774 8261, or by e-mail to eva.kruse@karobio.se.

 
For further information please contact:

Per Bengtsson, CEO
Phone: +46 76 002 6020

 

About Karo Bio

Karo Bio is a research and development company focused on innovative drugs for large medical needs. The foundation for operations is a unique knowledge of nuclear receptors as target proteins for the development of novel pharmaceuticals and the related mechanisms of action, as well as experience and expertise in preclinical and clinical development.

Karo Bio is active in preclinical development in the areas of neuropsychiatry, inflammation, autoimmune diseases, cancer and women’s health. The company has a number of strategic collaborations with big pharma.

Karo Bio is based in Huddinge, Sweden. The company has around 55 employees and is listed on NASDAQ OMX Stockholm (Reuters: KARO.ST).

Karo Bio publishes this information in accordance with the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was published on May 22, 2012, at 2:00 pm CET.

This press release is also available online at: www.karobio.se and www.newsroom.cision.com

Tags:

About Us

Karo Pharma is a specialty pharma company that develops and markets products to pharmacies and directly to healthcare providers. The share is listed on Nasdaq Stockholm in the Mid Cap segment.